Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Data for EP-104GI
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy EPRX?
Source: NASDAQ.COM
- Clinical Trial Progress: Eupraxia Pharmaceuticals reported that in its ongoing Phase 1b/2a RESOLVE trial, EP-104GI demonstrated a reduction of 0.59 and 0.53 in EoEHSS Stage and Grade scores in the highest dose cohort at 36 weeks, reflecting significant improvements of 90% and 88%, indicating positive effects on both inflammatory and structural components of the disease.
- Eosinophil Count Reduction: At week 36, the peak eosinophil count fell by 72% from baseline, marking the largest reduction observed across all dose cohorts, showcasing the potential of EP-104GI in treating eosinophilic esophagitis.
- Good Safety Profile: Among the 31 patients treated, no drug-related serious adverse events were reported for EP-104GI, indicating a favorable tolerability profile that enhances its clinical applicability.
- Long-term Follow-up Data: With over 230 patient-months of follow-up data supporting the safety and efficacy of EP-104GI, this lays a strong foundation for future clinical applications and may enhance Eupraxia's competitive position in the eosinophilic esophagitis treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EPRX
Wall Street analysts forecast EPRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.210
Low
11.02
Averages
13.02
High
16.03
Current: 7.210
Low
11.02
Averages
13.02
High
16.03
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Data for EP-104GI
- Clinical Trial Progress: Eupraxia Pharmaceuticals reported that in its ongoing Phase 1b/2a RESOLVE trial, EP-104GI demonstrated a reduction of 0.59 and 0.53 in EoEHSS Stage and Grade scores in the highest dose cohort at 36 weeks, reflecting significant improvements of 90% and 88%, indicating positive effects on both inflammatory and structural components of the disease.
- Eosinophil Count Reduction: At week 36, the peak eosinophil count fell by 72% from baseline, marking the largest reduction observed across all dose cohorts, showcasing the potential of EP-104GI in treating eosinophilic esophagitis.
- Good Safety Profile: Among the 31 patients treated, no drug-related serious adverse events were reported for EP-104GI, indicating a favorable tolerability profile that enhances its clinical applicability.
- Long-term Follow-up Data: With over 230 patient-months of follow-up data supporting the safety and efficacy of EP-104GI, this lays a strong foundation for future clinical applications and may enhance Eupraxia's competitive position in the eosinophilic esophagitis treatment market.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Trial Data for Eosinophilic Esophagitis Treatment
- Clinical Trial Results: Eupraxia Pharmaceuticals reported that up to 76% of patients achieved remission in the Phase 1b/2a portion of its RESOLVE trial, with no serious safety concerns, indicating both efficacy and safety of the treatment.
- Remission Rate Analysis: The EP-104GI study revealed that 59% of patients achieved remission at 12 weeks, increasing to 76% at 24 weeks, alongside improvements in swallowing difficulty scores and key disease markers, showcasing the treatment's significant effectiveness.
- New Technology Application: A new cohort utilizing improved catheter delivery demonstrated significantly better outcomes, with the treatment well tolerated across all dose levels and no serious adverse events reported, further validating the safety of the treatment.
- Market Reaction: EPRX became a trending ticker on Stocktwits, reflecting investor interest in its positive clinical data, which may drive the company's future market performance and bolster investor confidence.
See More
Eupraxia Pharmaceuticals Reports Q4 Net Loss of $16.7 Million
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $16.7 million for Q4 2025, compared to a net loss of $7.5 million in Q4 2024, indicating ongoing pressures in R&D and operations.
- Increased Cash Reserves: As of December 31, 2025, the company had cash reserves of $80.5 million, a significant increase from $33.1 million at the end of Q4 2024, reflecting positive developments in financing efforts.
- Optimistic Funding Outlook: The company anticipates that its existing cash reserves, along with proceeds from the offering and potential future exercise of in-the-money warrants, will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future growth.
- Public Offering Plan: Eupraxia Pharmaceuticals has filed for a proposed public share offering aimed at further enhancing liquidity to support its R&D and market expansion strategies.
See More
Eupraxia Completes Public Offering of 7.6 Million Shares
- Successful Financing: Eupraxia Pharmaceuticals has successfully closed a public offering of 7.6 million common shares, raising approximately $63.2 million, which will significantly enhance its research capabilities for EP-104GI targeting eosinophilic esophagitis and facilitate the achievement of multiple development milestones.
- Clear Use of Proceeds: The company intends to allocate the funds primarily towards clinical trials for EP-104GI, including ongoing Phase 2 trials and preparations for a Phase 3 trial, thereby accelerating the product's market readiness to meet demand.
- Market Expansion Plans: Eupraxia will also use a portion of the proceeds to expedite clinical studies in additional gastrointestinal indications, such as esophageal strictures and fibrostenotic Crohn's disease, further broadening its product pipeline and enhancing market competitiveness.
- Strategic Investment: This fundraising not only supports the advancement of existing projects but also funds the development of new pipeline candidates and strengthens corporate infrastructure, ensuring sustainable growth and demonstrating the company's long-term commitment to the biotechnology sector.
See More
Eupraxia Pharmaceuticals Prices Public Offering
- Offering Pricing: Eupraxia Pharmaceuticals has priced its public offering at $7.00 per share for 6.43 million common shares and 1.43 million pre-funded warrants, aiming for gross proceeds of approximately $55 million before expenses, indicating the company's ability to raise capital in the market.
- Market Reaction: Following the announcement of the public offering, Eupraxia's shares fell by 9.3% to $7.40 in premarket trading, reflecting a negative market response and investor concerns regarding the company's future prospects.
- Underwriter Team: Cantor and LifeSci Capital are acting as joint book-running managers for the offering, with Bloom Burton and Craig-Hallum serving as co-managers, demonstrating the support from multiple parties in the financing process.
- Use of Proceeds: The funds raised from this offering are intended to support Eupraxia's research and development as well as operational needs, aiming to advance its product pipeline, although the negative market reaction highlights the challenges the company faces in executing its long-term growth strategy.
See More
Eupraxia Pharmaceuticals Prices $55 Million Public Offering
- Offering Size: Eupraxia Pharmaceuticals has priced a public offering at $55 million, expected to close around February 20, 2026, with proceeds aimed at advancing key programs and expanding its proprietary Diffusphere technology.
- Program Development: The company plans to utilize the funds to advance its lead programs, including EP-104GI, currently in Phase 1b/2 RESOLVE trial, with topline data from the Phase 2b expected in Q3 2026.
- Financial Position: As of September 30, 2025, Eupraxia reported $89 million in cash, and with the new offering, it projects a funding runway into the first half of 2028, supporting multiple late-stage programs and pipeline expansion.
- Stock Performance: EPRX has traded between $2.68 and $9.32 over the past year, closing at $8.16, down 0.85%, and showing a pre-market decline of over 9% to $7.40, indicating cautious market sentiment regarding the offering.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Data for EP-104GI
- Clinical Trial Progress: Eupraxia Pharmaceuticals reported that in its ongoing Phase 1b/2a RESOLVE trial, EP-104GI demonstrated a reduction of 0.59 and 0.53 in EoEHSS Stage and Grade scores in the highest dose cohort at 36 weeks, reflecting significant improvements of 90% and 88%, indicating positive effects on both inflammatory and structural components of the disease.
- Eosinophil Count Reduction: At week 36, the peak eosinophil count fell by 72% from baseline, marking the largest reduction observed across all dose cohorts, showcasing the potential of EP-104GI in treating eosinophilic esophagitis.
- Good Safety Profile: Among the 31 patients treated, no drug-related serious adverse events were reported for EP-104GI, indicating a favorable tolerability profile that enhances its clinical applicability.
- Long-term Follow-up Data: With over 230 patient-months of follow-up data supporting the safety and efficacy of EP-104GI, this lays a strong foundation for future clinical applications and may enhance Eupraxia's competitive position in the eosinophilic esophagitis treatment market.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Trial Data for Eosinophilic Esophagitis Treatment
- Clinical Trial Results: Eupraxia Pharmaceuticals reported that up to 76% of patients achieved remission in the Phase 1b/2a portion of its RESOLVE trial, with no serious safety concerns, indicating both efficacy and safety of the treatment.
- Remission Rate Analysis: The EP-104GI study revealed that 59% of patients achieved remission at 12 weeks, increasing to 76% at 24 weeks, alongside improvements in swallowing difficulty scores and key disease markers, showcasing the treatment's significant effectiveness.
- New Technology Application: A new cohort utilizing improved catheter delivery demonstrated significantly better outcomes, with the treatment well tolerated across all dose levels and no serious adverse events reported, further validating the safety of the treatment.
- Market Reaction: EPRX became a trending ticker on Stocktwits, reflecting investor interest in its positive clinical data, which may drive the company's future market performance and bolster investor confidence.
See More
Eupraxia Pharmaceuticals Reports Q4 Net Loss of $16.7 Million
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $16.7 million for Q4 2025, compared to a net loss of $7.5 million in Q4 2024, indicating ongoing pressures in R&D and operations.
- Increased Cash Reserves: As of December 31, 2025, the company had cash reserves of $80.5 million, a significant increase from $33.1 million at the end of Q4 2024, reflecting positive developments in financing efforts.
- Optimistic Funding Outlook: The company anticipates that its existing cash reserves, along with proceeds from the offering and potential future exercise of in-the-money warrants, will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future growth.
- Public Offering Plan: Eupraxia Pharmaceuticals has filed for a proposed public share offering aimed at further enhancing liquidity to support its R&D and market expansion strategies.
See More
Eupraxia Completes Public Offering of 7.6 Million Shares
- Successful Financing: Eupraxia Pharmaceuticals has successfully closed a public offering of 7.6 million common shares, raising approximately $63.2 million, which will significantly enhance its research capabilities for EP-104GI targeting eosinophilic esophagitis and facilitate the achievement of multiple development milestones.
- Clear Use of Proceeds: The company intends to allocate the funds primarily towards clinical trials for EP-104GI, including ongoing Phase 2 trials and preparations for a Phase 3 trial, thereby accelerating the product's market readiness to meet demand.
- Market Expansion Plans: Eupraxia will also use a portion of the proceeds to expedite clinical studies in additional gastrointestinal indications, such as esophageal strictures and fibrostenotic Crohn's disease, further broadening its product pipeline and enhancing market competitiveness.
- Strategic Investment: This fundraising not only supports the advancement of existing projects but also funds the development of new pipeline candidates and strengthens corporate infrastructure, ensuring sustainable growth and demonstrating the company's long-term commitment to the biotechnology sector.
See More
Eupraxia Pharmaceuticals Prices Public Offering
- Offering Pricing: Eupraxia Pharmaceuticals has priced its public offering at $7.00 per share for 6.43 million common shares and 1.43 million pre-funded warrants, aiming for gross proceeds of approximately $55 million before expenses, indicating the company's ability to raise capital in the market.
- Market Reaction: Following the announcement of the public offering, Eupraxia's shares fell by 9.3% to $7.40 in premarket trading, reflecting a negative market response and investor concerns regarding the company's future prospects.
- Underwriter Team: Cantor and LifeSci Capital are acting as joint book-running managers for the offering, with Bloom Burton and Craig-Hallum serving as co-managers, demonstrating the support from multiple parties in the financing process.
- Use of Proceeds: The funds raised from this offering are intended to support Eupraxia's research and development as well as operational needs, aiming to advance its product pipeline, although the negative market reaction highlights the challenges the company faces in executing its long-term growth strategy.
See More
Eupraxia Pharmaceuticals Prices $55 Million Public Offering
- Offering Size: Eupraxia Pharmaceuticals has priced a public offering at $55 million, expected to close around February 20, 2026, with proceeds aimed at advancing key programs and expanding its proprietary Diffusphere technology.
- Program Development: The company plans to utilize the funds to advance its lead programs, including EP-104GI, currently in Phase 1b/2 RESOLVE trial, with topline data from the Phase 2b expected in Q3 2026.
- Financial Position: As of September 30, 2025, Eupraxia reported $89 million in cash, and with the new offering, it projects a funding runway into the first half of 2028, supporting multiple late-stage programs and pipeline expansion.
- Stock Performance: EPRX has traded between $2.68 and $9.32 over the past year, closing at $8.16, down 0.85%, and showing a pre-market decline of over 9% to $7.40, indicating cautious market sentiment regarding the offering.
See More
